KilickesmezKOKocaşBYildizA. Comparison of long-term outcomes in real-world patients between resolute zotarilumus-eluting and paclitaxel-eluting stents in small vessel. Angıology. 2016;67(5):490–495.
2.
DagenaisGRPogueJFoxKSimoonsMLYusufS. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368(9535):581–588.
3.
YusufSSleightPPogueJBoschJDaviesRDagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(10):145–153.
4.
ONTARGET Investigators, YusufSTeoKKPogueJ. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
